Clinical Trial Update: Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sublingual TNX-102 SL Tablet for fibromyalgia was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia
• Myofascial Pain Syndrome

Drugs mentioned

• TNX-102 SL Tablet

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: Fibromyalgia, Myofascial Pain Syndromes | Phase 3 | Status: TERMINATED | Results posted: 2025-02-25